Skip to main content

Table 6 Summary of efficacy according to EGFR sensitizing mutation (common or rare) and common sensitizing EGFR mutation type (exon 19 deletion or L858R) and first-line treatment (EGFR TKI or chemotherapy) used in patients carrying common sensitizing EGFR mutations

From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

  EGFR sensitizing mutation (n = 132) mutation (n = 131) Common sensitizing EGFR mutation (n = 112)
   Type of mutation First-line treatment
Endpoint Common Rare Del 19 L858R TKI CT
Evaluable 112 20 82 30 96 16
Response, n (%)
 CR 3 (3.1) 0 (0.0) 2 (2.9) 1 (3.6) 3 (3.1) 1 (6.3)
 PR 48 (50.0) 2 (12.5) 35 (51.5) 13 (46.4) 48 (50.0) 2 (12.5)
 SD 38 (39.6) 8 (50.0) 27 (39.7) 11 (39.3) 38 (39.6) 11 (68.8)
 PD 7 (7.3) 6 (37.5) 4 (5.9) 3 (10.7) 7 (7.3) 2 (12.5)
ORR, n (%) 51 (53.1) 2 (12.5) 37 (54.4) 14 (50.0) 51 (53.1) 3 (18.8)
 95% CI 42.7–63.4 1.6–38.4 41.9–66.5 30.6–69.4 42.7–63.4 4.0–45.6
DCR, n (%) 89 (92.7) 10 (62.5) 64 (94.1) 25 (89.3) 89 (92.7) 14 (87.5)
 95% CI 85.6–97.0 35.4–84.8 85.6–98.4 71.8–97.7 85.6–97.0 61.7–98.4
  1. CI Confidence interval, CR Complete response, DCR Disease control rate, ORR Overall response rate, PR Partial response, PD Progressive disease, SD Stable disease
\